
    
      Prospective, randomized trial where patients will be randomly assigned to 1 of 3 groups, each
      with a sample size of 25 (total n=75). Group 1 will receive DEXYCU + Omidria (Omidria =
      ketorolac + phenylephrine), group 2 will receive DEXTENZA + Omidria, and group 3 will receive
      prednisolone acetate + Omidria. Each of the drug combinations used in each of the 3 groups is
      standard of care, FDA approved, and will be used on label. 1:1:1, n=75 with 25 subjects
      assigned to each of the 3 groups.
    
  